METTL3 and posterior cortical atrophy: Further work is now warranted to understand the complex mechanisms underpinning these novel findings and to determine whether pharmacological inhibition of METTL3 by drugs in phase I clinical trials for advanced solid tumours (clinicaltrials.gov: NCT05584111) may be relevant to subsets of PCa patients.